After the CARDAMON trial update, what do we know about the role of ASCT and K maintenance in NDMM?

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Rakesh Popat, UCL...

How might the iberdomide safety profile be critical for its future applications?

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer...

After the latest follow up of the MASTER trial, can we safely implement MRD-guided frontline treatment in the clinic?

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke...

The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Eli Muchtar, Mayo...

IMWG clinical practice guidelines for the treatment of multiple myeloma-related bone disease

After evaluating the existing literature and grading recommendations using the Grading of Recommendations,...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

FDA places a clinical hold on allogeneic CAR T cell trials

On October 7, 2021, the U.S. Food and Drug Administration (FDA) placed a clinical hold on a series of trials investigating the use of...

End of the LYRA study: DARA + VCd induction therapy followed by DARA maintenance

Daratumumab or DARA is a human IgG kappa monoclonal antibody and is approved as monotherapy or in combination with...

How might the iberdomide safety profile be critical for its future applications?

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer...

Editorial theme | Carfilzomib and cardiovascular adverse events

The field of multiple myeloma (MM) research has progressed rapidly over the recent decade, and the advent of promising novel agents is...